Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles
Published by Oxford University Press on behalf of the British Society for Rheumatology 2023..
OBJECTIVES: The 2016 ACR-EULAR Response Criteria for JDM was developed as a composite measure with differential weights of six core set measures (CSMs) to calculate a Total Improvement Score (TIS). We assessed the contribution of each CSM, representation of muscle-related and patient-reported CSMs towards improvement, and frequency of CSM worsening across myositis response criteria (MRC) categories in validation of MRC.
METHODS: Data from JDM patients in the Rituximab in Myositis trial (n = 48), PRINTO JDM trial (n = 139), and consensus patient profiles (n = 273) were included. Observed vs expected CSM contributions were compared using Sign test. Characteristics of MRC categories were compared by Wilcoxon tests with Bonferroni adjustment. Spearman correlation of changes in TIS and individual CSMs were examined. Agreement between physician-assessed change and MRC categories was evaluated by weighted Cohen's kappa.
RESULTS: Of 457 JDM patients with IMACS CSMs and 380 with PRINTO CSMs, 9-13% had minimal, 19-23% had moderate and 41-50% had major improvement. The number of improved and absolute percentage change of CSMs increased by MRC improvement level. Patients with minimal improvement by MRC had a median of 0-1 CSM worsened, and those with moderate/major improvement had a median of zero worsening CSMs. Of patients improved by MRC, 94-95% had improvement in muscle strength and 93-95% had improvement in ≥1 patient-reported CSM. IMACS and PRINTO CSMs performed similarly. Physician-rated change and MRC improvement categories had moderate-to-substantial agreement (Kappa 0.5-0.7).
CONCLUSION: The ACR-EULAR MRC perform consistently across multiple studies, supporting its further use as an efficacy end point in JDM trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - 62(2023), 11 vom: 02. Nov., Seite 3680-3689 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Hanna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 09.11.2023 Date Revised 10.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/rheumatology/kead111 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354353896 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354353896 | ||
| 003 | DE-627 | ||
| 005 | 20240210232510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/kead111 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM354353896 | ||
| 035 | |a (NLM)36929918 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Hanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.11.2023 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by Oxford University Press on behalf of the British Society for Rheumatology 2023. | ||
| 520 | |a OBJECTIVES: The 2016 ACR-EULAR Response Criteria for JDM was developed as a composite measure with differential weights of six core set measures (CSMs) to calculate a Total Improvement Score (TIS). We assessed the contribution of each CSM, representation of muscle-related and patient-reported CSMs towards improvement, and frequency of CSM worsening across myositis response criteria (MRC) categories in validation of MRC | ||
| 520 | |a METHODS: Data from JDM patients in the Rituximab in Myositis trial (n = 48), PRINTO JDM trial (n = 139), and consensus patient profiles (n = 273) were included. Observed vs expected CSM contributions were compared using Sign test. Characteristics of MRC categories were compared by Wilcoxon tests with Bonferroni adjustment. Spearman correlation of changes in TIS and individual CSMs were examined. Agreement between physician-assessed change and MRC categories was evaluated by weighted Cohen's kappa | ||
| 520 | |a RESULTS: Of 457 JDM patients with IMACS CSMs and 380 with PRINTO CSMs, 9-13% had minimal, 19-23% had moderate and 41-50% had major improvement. The number of improved and absolute percentage change of CSMs increased by MRC improvement level. Patients with minimal improvement by MRC had a median of 0-1 CSM worsened, and those with moderate/major improvement had a median of zero worsening CSMs. Of patients improved by MRC, 94-95% had improvement in muscle strength and 93-95% had improvement in ≥1 patient-reported CSM. IMACS and PRINTO CSMs performed similarly. Physician-rated change and MRC improvement categories had moderate-to-substantial agreement (Kappa 0.5-0.7) | ||
| 520 | |a CONCLUSION: The ACR-EULAR MRC perform consistently across multiple studies, supporting its further use as an efficacy end point in JDM trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a JDM | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a myositis | |
| 650 | 4 | |a outcome assessment | |
| 650 | 4 | |a outcome measure | |
| 650 | 4 | |a response criteria | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Saygin, Didem |e verfasserin |4 aut | |
| 700 | 1 | |a Douglas, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Wilkerson, Jesse |e verfasserin |4 aut | |
| 700 | 1 | |a Erman, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Pistorio, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a McGrath, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Reed, Ann M |e verfasserin |4 aut | |
| 700 | 1 | |a Oddis, Chester V |e verfasserin |4 aut | |
| 700 | 1 | |a Bracaglia, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a van Royen-Kerkhof, Annet |e verfasserin |4 aut | |
| 700 | 1 | |a Bica, Blanca |e verfasserin |4 aut | |
| 700 | 1 | |a Dolezalova, Pavla |e verfasserin |4 aut | |
| 700 | 1 | |a Ferriani, Virginia P L |e verfasserin |4 aut | |
| 700 | 1 | |a Flato, Berit |e verfasserin |4 aut | |
| 700 | 1 | |a Bernard-Medina, Ana G |e verfasserin |4 aut | |
| 700 | 1 | |a Herlin, Troels |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Frederick W |e verfasserin |4 aut | |
| 700 | 1 | |a Vencovsky, Jiri |e verfasserin |4 aut | |
| 700 | 1 | |a Ruperto, Nicolino |e verfasserin |4 aut | |
| 700 | 1 | |a Aggarwal, Rohit |e verfasserin |4 aut | |
| 700 | 1 | |a Rider, Lisa G |e verfasserin |4 aut | |
| 700 | 0 | |a International Myositis Assessment and Clinical Studies Group (IMACS) and Paediatric Rheumatology INternational Trials Organization (PRINTO) |e verfasserin |4 aut | |
| 700 | 1 | |a Pinal-Fernandez, Iago |e investigator |4 oth | |
| 700 | 1 | |a Kim, Susan |e investigator |4 oth | |
| 700 | 1 | |a Ascherman, Dana |e investigator |4 oth | |
| 700 | 1 | |a Schiffenbauer, Adam |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 62(2023), 11 vom: 02. Nov., Seite 3680-3689 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:11 |g day:02 |g month:11 |g pages:3680-3689 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/kead111 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 11 |b 02 |c 11 |h 3680-3689 | ||